bms-813160
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01049165)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O- Mol. weight
- 484.65 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594419 ↗
Also known as
- bms-813160
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04123379 | Phase 2 | Nov 30, 2019 | Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai |
| NCT03767582 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Bristol-Myers Squibb, Johns Hopkins University |
| NCT03496662 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH), Washington University in St. Louis |
| NCT03184870 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2017 | Bristol-Myers Squibb |
| NCT01752985 | Phase 2 | Mar 1, 2013 | Bristol-Myers Squibb |
| NCT01049165 | Phase 1 | Feb 1, 2010 | Bristol-Myers Squibb |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 6 | 3 | 2 | 2010 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2018 |
6 organizations
Page 1 / 1